Boehringer Ingelheim’s Pagnotta Talks Adalimumab And Interchangeability
As Cyltezo Rival To Humira Hits US, Firm Says It Is ‘Uniquely Positioned’ In Biosimilars Market
As Boehringer Ingelheim launches the first – and so far, only – interchangeable US adalimumab biosimilar, the firm’s biosimilar commercial brand lead Stephen Pagnotta talks to Generics Bulletin about how the interchangeability designation puts the firm in a unique position when it comes to competing with Humira.
